迪瑞醫療(300396.SZ)獲得三項醫療器械註冊證
格隆匯9月17日丨迪瑞醫療(300396.SZ)公佈,公司於近日取得由吉林省藥品監督管理局頒發的3項《醫療器械註冊證》。
其中,產品名稱:全自動血細胞分析儀;臨牀用途:用於測試血液中紅細胞、血小板、白細胞的數目以及體積分佈,血紅蛋白的濃度,為臨牀診斷提供依據;分類:Ⅱ。
產品名稱:全自動五分類血細胞分析儀;臨牀用途:用於測試血液中紅細胞、血小板、白細胞的數目以及體積分佈,血紅蛋白的濃度,同時提供白細胞分類的散點圖,為臨牀診斷提供依據;分類:Ⅱ。
產品名稱:全自動生化分析儀;臨牀用途:用於血清、血漿、尿液、胸腹水和腦脊液生物化學指標的檢驗和分析,為臨牀診斷提供依據;分類:Ⅱ。
上述《醫療器械註冊證》均為延續註冊產品,上述產品的取得,延續了公司產品種類,將進一步增強公司產品的綜合競爭力,有利於進一步提高公司的市場拓展能力,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.